← Back to Dashboard
Litigation Stage Tracker
Rapid GrowthEmerging
Formation
Active Litigation
Maturation
<45
45–55
55–70
70+
Keytruda Organ Failure
OpenFASTPharma
50+
Total Cases
Causation
Pembrolizumab works by blocking PD-1, releasing immune system brakes on T-cells. This mechanism inherently risks autoimmune attack on healthy organs. Plaintiffs allege Merck understated the frequency and severity of immune-related adverse events (irAEs) including hepatitis (liver failure), pneumonitis (lung inflammation), colitis, nephritis (kidney failure), and myocarditis (heart inflammation). FDA adverse event reports show hundreds of fatal irAE cases. Published studies in JAMA Oncology report irAE rates of 15-20% with grade 3-5 events in 3-5% of patients.
Defendants
| Entity | Role | Note |
|---|---|---|
| Merck & Co. | Manufacturer | Sole manufacturer and marketer of Keytruda (pembrolizumab) — world's top-selling drug |
| Merck Sharp & Dohme LLC | Operating Subsidiary | US operating entity for Keytruda distribution |
Litigation Timeline
Sep 2014
FDA approves Keytruda for advanced melanoma (first approval)
2017-2023
FDA expands Keytruda to 30+ cancer indications — becoming most widely used immunotherapy
2023
Keytruda reaches $25B annual revenue — world's best-selling drug
2024
First wave of failure-to-warn lawsuits filed against Merck
2025
Case inventory building; plaintiff steering committee forming
2026
~50 cases filed. JPML MDL petition anticipated
Intelligence Signals
No signals yet. Signals populate automatically when scrapers run.
Key Facts
- Status
- active
Geographic Exposure
·Various federal districts (Pre-MDL — no consolidation yet)
·New Jersey (Merck headquarters — expected filing hub)
·California, Texas, Florida (high filing volume states)
·JPML petition for MDL consolidation expected
Eligibility Criteria
- ✓Received Keytruda (pembrolizumab) treatment
- ✓Developed immune-related organ failure (hepatitis, pneumonitis, colitis, nephritis, myocarditis)
- ✓Organ failure was severe (Grade 3+) or fatal
- ✓Alleges inadequate warning of irAE severity and management protocols